Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelegy Ellipta in symptomatic COPD
NCT05535972Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Oct 2022; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05535972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535972.